Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Must admit it is taking a lot longer than I envisaged. I expected the deal to be announced by now. My understanding was that as part of the deal, the partner would be investing in Dest. Could it be that what is holding the deal up, as the share price has risen from 32p up to 60p and they have to agree at what price to invest at. Just my thoughts.
Iain in action
https://t.co/IjCYFVxrla
1. No trading update issued in Jan as one was issued in December.
2. The Chad production reported in the update in December is the latest public figure Savannah has released.
3. South Sudan acquisition. Guidance for deal completion remains H1 2023. Savannah will update the market as appropriate should this change.
Hi pjmcgra, I stopped posting on Polx chat board as I didn't want to waste my time with a few idiots on that board. All I ever tried to do was provide info to help people on that board. As you can see most of what I suggested was true in the end.
As I have stated before my research has led me to believe that our partner for M3 will be a medium size pharma and not a large pharma. The Mcap is likely to be under a Billion dollars. However I do expect our partner for XF-73 to be a Major pharma, as I expect XF-73 to become a blockbuster drug. Those are my thoughts and we will find out very soon.
Really, if that was the case then I would expect them to take part in the placing and not buying as they have. Also why would they do a placing when they cash runway into 2024. Do some research before posting absolute rubbish.
All the evidence suggests that XF-73 will be a blockbuster drug. Partnering discussions were supposed to start in 2023 and we have had it confirmed that discussions started late 2022, earlier than expected. The US govt approaching Dest and paying for pre clinical trials for XF-73. Once pre clinical trials have met the endpoints I fully expect them to pay for clinical trials. All the reports in the media suggest governments are in desperate need for AMR drugs.
My thoughts after this mornings Rns. Cash runway into 2024, which is a start, but I would like to see the hRPC data package sold for a few million and last I heard was that quite a few companies were interested. A few million should come from the Fosun partnerships. That should extend runway into mid 2024. I should point out that Fosun are paying the wages of a few of our staff as part of the deal. Regarding the exosomes our costs are paid for by partners and with no trials running our cash burn should be much lower this year. That should give them plenty of time to prove up the data and sign at least one exosome deal this year. We just need to get one deal over the line with a decent upfront payment and that will be transformational for the company. I still hold all my shares and believe Iain will turn it around, he is not going anywhere until he has. GLA.